Osiris To Present 15 Advanced Clinical And Scientific Abstracts

Experts to host a variety of presentations at the Symposium on Advanced Wound Care & Wound Healing Society Spring Conference, April 13 – April 17, 2016, in Atlanta, Georgia

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced clinical and scientific research at the Symposium on Advanced Wound Care (SAWC) and Wound Healing Society Spring Conference, the nation’s largest interdisciplinary wound care event within the clinical field.

“The Use of Viable Cryopreserved Human Placental Membrane in the Management of Complex Diabetic Foot Ulcers with Exposed Tendon or Bone”

Osiris will be presenting a total of 15 abstracts. Six clinical studies will demonstrate the positive outcomes of Osiris’ cryopreserved placental membrane, Grafix^®, cryopreserved placental tissue, Stravix^™, and cryopreserved skin allograft, TruSkin^™. The nine scientific studies demonstrate the characterization and benefits of placental and skin allografts.

Dr. Robert Frykberg, DPM, MPH, will be presenting a Late Breaking Abstract, entitled, “The Use of Viable Cryopreserved Human Placental Membrane in the Management of Complex Diabetic Foot Ulcers with Exposed Tendon or Bone,” on Friday, April 15. The presentation summarizes the first prospective study that focuses on patients with wounds that have exposed bone and tendon; a patient group that is usually excluded from clinical studies. The patient group also had severe co-morbidity with a mean wound duration of 7.5 months before treated with Grafix. The proportion of patients that reached 100% granulation at 16 weeks was 96.3%. Dr. Frykberg will present the positive clinical outcomes demonstrated and their impact on the wound care field.

The scientific poster, “Human Viable Cryopreserved amniotic membrane (hVCAM) induces angiogenesis in a nestin-driven green fluorescent protein (ND-GFP) transgenic mouse model,” showed for the first time hVCAM angiogenic potential in vivo. HVCAM supports both new blood vessel formation and their maturation in vivo. A unique ND-GFP transgenic mouse model allowing dynamic imaging of new blood vessel formation was utilized for the first time to test placental tissue functionality. The WHS abstract review committee selected this study for a podium presentation on Friday, April 15, and for the WHS Industrial Research & Development Poster Award.

The scientific poster, “Tracking Cell Persistence in Chronic Wounds after Application of Viable Placental Allografts,” describes a newly developed methodology allowing evaluation of viable cell fate in tissue allografts in vivo in a diabetic mouse chronic wound model. The study shows that viable cells in human placental allograft persist for 1 week post- application to the wound. This poster has been selected for a Research Poster Critique during Research Poster Walking Grand Rounds.

Scientific and Clinical Abstracts:

• Late Breaking Abstract – selected for a podium presentation “The Use of Viable Cryopreserved Human Placental Membrane in the Management of Complex Diabetic Foot Ulcers with Exposed Tendon or Bone” (Session 28 Friday, April 15, 2016; 10:30 am - 11:30 am)
• “Surgical Use of Cryopreserved Viable Placental Membranes (CVPM) for Lower Extremity Wounds” (Abstract #CS-035)
• “Soft-tissue Reconstruction of Head and Neck Surgical Sites with a Viable Intact Cryopreserved Human Placental Matrix” (Abstract #CS-097)
• “The Use of Viable Cryopreserved Placental Membrane (vCPM) in the Treatment of Complex Wounds with Exposed Muscle, Tendon, and Bone” (Abstract #CS-145)
• “Utilizing a Viable Intact Cryopreserved Human Placental Membrane in the Closure of Recalcitrant and Atypical Wounds” (Abstract #CS-156)
• “Comprehensive Wound Closure Using Viable Intact Cryopreserved Human Placental Membrane” (Abstract #CS-166)
• WHS Industrial Research & Development Poster Award “Human Viable Cryopreserved amniotic membrane (hVCAM) induces angiogenesis in a nestin-driven green fluorescent protein (ND-GFP) transgenic mouse model” (Abstract #K1.03; SESSION K1: Angiogenesis Friday April 15, 2:15 pm - 3:15 pm)
• Research Poster Critique Recognition “Tracking Cell Persistence in Chronic Wounds after Application of Viable Placental Allografts” (Abstract #LB-012; Friday, April 15 from 10:30 am - 11:30 am)
• “Antimicrobial Peptides in Human Cryopreserved Viable Placental Membrane Inhibit Bacterial Growth” (Abstract #LB-031)
• “Effect of Human Cryopreserved Viable Placental Membrane (hCVPM) on M1 macrophages in vitro” (Abstract #P.II05)
• “Up-regulation of anti-inflammatory and anti-microbial activity in human cryopreserved viable placental membrane in the presence of bacterial antigens” (Abstract #P.IB11)
• “Single layer viable placental allografts show a superior dynamic response over multi-layer non-viable allografts to an in vitro wound microenvironment” (Abstract #P.NTA09)
• “A novel cryopreserved placental tissue for surgical soft tissue reinforcement” (Abstract #LB-002)
• “Development of a Novel Viable Cryopreserved Skin Allograft (vCSA)” (Abstract #CS-169)
• “Characterization of a Novel Viable Cryopreserved Skin Allograft (vCSA)” (Abstract #LB-043)

Osiris Therapeutics will also be exhibiting at the Symposium on Advanced Wound Care meeting at booth 635. The event runs from April 13 through April 17, 2016 at the Georgia World Congress Center in Atlanta, Georgia.

About Osiris Therapeutics

Osiris Therapeutics, Inc., based in Columbia, Maryland, is a leader in researching, developing and marketing cellular regenerative medicine products that improve the health and lives of patients and lower overall healthcare costs. Having developed the world’s first approved stem cell drug, Osiris works to further advance the medical field. Osiris’ research and development in biotechnology focuses on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO^4®, a viable bone matrix, Cartiform^®, a viable osteochondral allograft, Grafix, a cryopreserved placental membrane, TruSkin, a viable human skin allograft and Stravix, a durable placental allograft.

Osiris, Grafix and Cartiform are registered trademarks of Osiris Therapeutics, Inc.; TruSkin and Stravix are trademarks of Osiris Therapeutics, Inc. BIO⁴ is a registered trademark of Stryker Corporation (NYSE: SYK). More information can be found on the company’s website, www.Osiris.com. (OSIR-G)

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy biologic drug candidates and marketed Biosurgery products (including Grafix, BIO⁴, Cartiform, TruSkin and Stravix); our cash needs; patents, trademarks and other proprietary rights; the safety and ability of our products and potential products to treat disease; our ability to supply a sufficient amount of our marketed products or product candidates and, if approved or otherwise commercially available, products to meet demand; our costs to comply with governmental regulations; our plans for sales and marketing; our plans regarding facilities; types of regulatory frameworks we expect will be applicable to our products and potential products; results of our scientific research; the timing of our amended 2015 filings; and the engagement of our successor accounting firm. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled “Risk Factors” in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.